ReviewThe pharmacogenomics journal2011
The pharmacogenetics and pharmacogenomics of asthma therapy.
Review in The pharmacogenomics journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Standard medical therapy with vs. without nebulised magnesium for children with asthma decompensation.European journal of pediatrics · 2024Pooled it
- Trial
- Circulating MicroRNAs and Treatment Response in Childhood Asthma.American journal of respiratory and critical care medicine · 2020Trial
- Trial
- Genetic variation in uncontrolled childhood asthma despite ICS treatment.The pharmacogenomics journal · 2016Trial
- A review of recent advances in gene therapy, pharmacogenomics, and genetic polymorphisms in asthma.Molecular biology reports · 2025Review
- Responsiveness of Inhaled Corticosteroid Treatment in Children with Asthma: The Role of rs242941 Polymorphism of CRHR1 Gene.Pulmonary therapy · 2023Article
- Beyond eNOS: Genetic influence in NO pathway affecting drug response.Genetics and molecular biology · 2022Article
- Clinical entities, phenotypes, causation, and endotypes based on selected asthma publications.Proceedings (Baylor University. Medical Center) · 2020Review
- Racial/Ethnic-Specific Differences in the Effects of Inhaled Corticosteroid Use on Bronchodilator Response in Patients With Asthma.Clinical pharmacology and therapeutics · 2019Article
- Glucocorticoid-Induced Transcription Factor 1 (GLCCI1) Variant Impacts the Short-Term Response to Intranasal Corticosteroids in Chinese Han Patients with Seasonal Allergic Rhinitis.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.The Journal of international medical research · 2017Review
- Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma.The pharmacogenomics journal · 2015Article
- Admixture of beneficial and unfavourable variants of GLCCI1 and FCER2 in Roma samples can implicate different clinical response to corticosteroids.Molecular biology reports · 2014Article
- Nocturnal asthma and the importance of race/ethnicity and genetic ancestry.American journal of respiratory and critical care medicine · 2014Article
- Association among ORMDL3 gene expression, 17q21 polymorphism and response to treatment with inhaled corticosteroids in children with asthma.The pharmacogenomics journal · 2013Article
- Role of biomarkers in understanding and treating children with asthma: towards personalized care.Pharmacogenomics and personalized medicine · 2013Review
- Delivering systems pharmacogenomics towards precision medicine through mathematics.Advanced drug delivery reviews · 2013Review
- Personalised medicine for cystic fibrosis: treating the basic defect.European respiratory review : an official journal of the European Respiratory Society · 2013Article
- Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells.Journal of clinical immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite the availability of several classes of asthma medications and their overall effectiveness, a significant portion of patients fail to respond to these therapeutic agents. Evidence suggests that genetic factors may partly mediate the heterogeneity in asthma treatment response. This review discusses important findings in asthma pharmacogenetic and pharmacogenomic studies conducted to date, examines limitations of these studies and, finally, proposes future research directions in this field. The focus will be on the three major classes of asthma medications: β-adrenergic receptor agonists, inhaled corticosteroids and leukotriene modifiers. Although many studies are limited by small sample sizes and replication of the findings is needed, several candidate genes have been identified. High-throughput technologies are also allowing for large-scale genetic investigations. Thus, the future is promising for a personalized treatment of asthma, which will improve therapeutic outcomes, minimize side effects and lead to a more cost-effective care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.